Dr. Kirby is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3705 W 15th St
Plano, TX 75075Phone+1 972-867-3577Fax+1 972-985-9433
Education & Training
University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 1980 - 1982- University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 1979 - 1980
- University of Kansas School of MedicineResidency, Internal Medicine, 1977 - 1979
University of Missouri-Columbia School of MedicineClass of 1976
Certifications & Licensure
TX State Medical License 1982 - 2025
KS State Medical License 1977 - 2013- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Fellow American College of Physicians
- Super Doctor SuperDoctors.com
Publications & Presentations
PubMed
- 395 citationsDocetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research...Stephen E. Jones, Frankie A. Holmes, Joyce O'Shaughnessy, Joanne L. Blum, Svetislava J. Vukelja
Journal of Clinical Oncology. 2009-03-10 - 127 citationsPhase II Study of Weekly Albumin-Bound Paclitaxel for Patients with Metastatic Breast Cancer Heavily Pretreated with TaxanesJoanne L. Blum, Michael Savin, Gerald Edelman, J. Pippen, Nicholas J. Robert
Clinical Breast Cancer. 2007-12-01 - 376 citationsPhase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast CancerStephen E. Jones, Michael Savin, Frankie A. Holmes, Joyce O'Shaughnessy, Joanne L. Blum
Journal of Clinical Oncology. 2006-12-01
Journal Articles
- Adjuvant Chemotherapy with Doxorubicin and Cyclophosphamide in Women with Rapidly Proliferating Node-Negative Breast CancerJones, S., Clark, G., Kirby, R., et al, Clinical Breast Cancer Research, Vol 3, No. 2, 2002
- Low Proliferation Rate of Invasive Node Negative Breast cancer Predicts for a Favorable Outcome Without Adjuvant Chemotherapy. Prospective evaluation of 669 Patients.Jones, S., Clark,, Kolester, S., Kirby, R., et al., Clinical Breast Cancer Research, 6/2001
- Randomized Double-Blind Prospective Trial to Evaluate the Effects of Sargramostim Versus Placebo in a Moderate Dose Flourouricil, Doxorubicin and Cyclophosphamide Adju...Jones, S.E., Schottstaedt, M.W., Duncan, LA, Kirby R.L, et al, Journal of Clinical Oncology Vol 14, No. 11, 1997
- Join now to see all
Press Mentions
Cell Competition May Explain Cancer Relapses, Research SuggestsNovember 7th, 2022- Tackling Resistance to HIF2 Drugs with an RNA-Based TherapyOctober 3rd, 2022
- National Cancer Institute Renews $11.5 Million Program of Excellence Award in Kidney CancerSeptember 19th, 2022
- Join now to see all
Committees
- Member, Mary Crowley Research Center Institutional Review Board 2019 - 2024
- Chairman 2015, Medical Center of Plano-Board of Trustees 2011 - 2015
- Chairman, Medical City Plano Institutional Review Board 2009 - 2024
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
